| Assessment Status | Rapid Review Complete |
| HTA ID | 22073 |
| Drug | Drospirenone/estetrol monohydrate |
| Brand | Drovelis® |
| Indication | Drospirenone/estetrol monohydrate is indicated for oral contraception. |
| Assessment Process | |
| Rapid review commissioned | 07/12/2022 |
| Rapid review completed | 23/01/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that drospirenone/estetrol monohydrate not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; June 2023
